



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 90414

**Title:** Circulating tumor cells as prognostic marker in pancreatic cancer

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05492281

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Consultant Cardiac Surgeon, Full Professor, Neurosurgeon, Research Scientist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Turkey

**Manuscript submission date:** 2023-12-03

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-12-03 16:06

**Reviewer performed review:** 2023-12-03 16:18

**Review time:** 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

Cancer is a major disease that causes poor prognosis in humans. In the past, the main focus was on early detection, early diagnosis and early treatment of tumors. However, how to better judge the prognosis is also crucial for the individual treatment of patients. Detection of CTC in the blood holds promise for early diagnosis, Yakar M. et al. reports. Studies have shown that high CTC levels are associated with more advanced stages, and more intensive treatment should be considered in cases of high CTC. Many other prognostic markers have been reported in the past. What are the advantages of using circulating tumor cells (CTCs) as markers over other proteins or oncogenes? A brief explanation is required in the discussion section, and the following references are cited.  
DOI: 10.1002/mco2.182 <https://doi.org/10.1002/VIW.20220052>